Provvedimento: Consortium Agreement - Rep. n° 540/2019 Prot. n° 81093 del 30/04/2019

Approvazione Consortium Agreement relativo al progetto Horizon 2020 “ConcePTION”, responsabile scientifico prof. Manzoli, partecipanti: Universitair Medisch Centrum Utrecht (UMCU; cordinator), The Netherlands; University of Ulster (ULST), United Kingdom; Uppsala Universitet (UPPS), Sweden; Biobanks and Biomolecular Resourcesresearch Infrastructure Consortium (BBMRI-ERIC), Austria; Alma Mater Studiorum - Università di Bologna (UNIBO), Italy; The European Institute for Innovation through Health Data (iHD), Belgium; Katholieke Universiteit Leuven (KUL), Belgium; Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom; Stichting Lareb (LAREB), The Netherlands;
Agenzia Regional di Sanita Tuscany (ARS), Italy; Karolinska Institutet (KI), Sweden; The Newcastle Upon Tyne Hospitals NHS Foundation Trust (NUTH), United Kingdom; University of KwaZulu-Natal (UKZN), South Africa; Universitetet I Oslo (UOSL), Norway; St George’s Hospital Medical School (SGUL), United Kingdom; European Institute for Women’s Health, CLG (EIWH), Ireland; Academisch Ziekenhuis Groningen (UMCG), The Netherlands; Orcion BV (ORC), The Netherlands; Institut National de la Santé Et de la Recherche Médicale (INSERM), France; BioNotus (BioNotus), Belgium; Centre Hospitalier Universitaire de Toulouse (CHUT), France; Università degli Studi di Ferrara (FERR), Italy; Swansea University (USWAN), United Kingdom; Universite de Geneve (UNIGE), Switzerland; European Forum for Good Clinical Practice (EFGCP), Belgium; The Synergist (Synergist), Belgium; Stichting ENTIS (European Network Teratology Information Services) Foundation (ENTIS), The Netherlands; The University of Manchester (UMAN), United Kingdom; Stockholms Lans Landsting (SCC), Sweden; Elevate BV (Elevate), The Netherlands; Terveyden Ja Hyvinvoinnin Laitos – National Institute for Health and Welfare (NIHW), Finland; Consiglio Nazionale Delle Richerche – CNR Institute of Clinical Physiology (CNR-IFC), Italy; Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana (FISABIO), Spain; ttopstart (TTOP), The Netherlands; The State of the Netherlands, represented by the Minister of Health, Welfare and Sport, on behalf of the Minister represented by Mr.Prof.dr.ir.J. Brug, Director-General of the National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu (RIVM)), The Netherlands; The European Medicines Agency (EMA), The Netherlands; Janssen Pharmaceutica NV (JAN), Belgium; Novartis Pharma AG (NVS), Switzerland; Sanofi-Aventis Recherche & Developpement (SARD), France; Takeda Development Centre Europe Ltd. (Takeda), United Kingdom; GlaxoSmithKline Research and Development Ltd. (GSK), United Kingdom; Eli Lilly and Company Limited (Lilly), United Kingdom; Pfizer Limited (Pfizer), United Kingdom; Bristol-Myers Squibb Company Corp (BMS), United States; Merck Kommanditgesellschaft auf Aktien (Merck), Germany; Novo Nordisk A/S (Novo), Denmark;UCB Biopharma SPRL (UCB), Belgium; AbbVie Inc (AbbVie), United States; Ellegaard Göttingen Minipigs A/S (Ellegaard), Denkmark; Covance Laboratories LTD (Covance), United Kingdom; Teva Pharmaceutical Industries Limited (Teva), Israel.